True North Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 17

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $825M

True North Therapeutics General Information

Description

Developer of innovative antibody therapeutics targeting the classical pathway of the complement system. The company's monoclonal antibody to treat cold agglutinin disease TNT009, selectively targets the classical pathway of the complement system and prevents the generation of critical inflammatory mediators and phagocytic markers not addressed by other therapeutic approaches that act by inhibiting the complement system further downstream.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 951 Gateway Boulevard
  • South San Francisco, CA 94080
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • 951 Gateway Boulevard
  • South San Francisco, CA 94080
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

True North Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 28-Jun-2017 $825M Completed Clinical Trials - Phase 1
6. Later Stage VC (Series D) 18-Oct-2016 Completed Clinical Trials - Phase 1
5. Secondary Transaction - Private Completed Clinical Trials - Phase 1
4. Later Stage VC (Series C) 03-Dec-2015 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 07-Apr-2015 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 17-Jun-2014 $22M $22M Completed Startup
1. Accelerator/Incubator Completed Startup
To view True North Therapeutics’s complete valuation and funding history, request access »

True North Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 29,166,580 $0.000100 $0.1 $1.2 $1.2 1x $1.2 21.6%
Series A 23,856,206 $0.000100 $0.08 $1 $1 1x $1 17.67%
To view True North Therapeutics’s complete cap table history, request access »

True North Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of innovative antibody therapeutics targeting the classical pathway of the complement system. The company's mo
Drug Discovery
South San Francisco, CA
17 As of 2016

San Rafael, CA
 

Karmiel, Israel
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

True North Therapeutics Competitors (63)

One of True North Therapeutics’s 63 competitors is BioMarin Pharmaceutical, a Formerly PE-Backed company based in San Rafael, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioMarin Pharmaceutical Formerly PE-Backed San Rafael, CA
Protalix Biotherapeutics Formerly VC-backed Karmiel, Israel
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Renova Therapeutics Venture Capital-Backed Carlsbad, CA
Cell Signaling Technology Corporation Danvers, MA
You’re viewing 5 of 63 competitors. Get the full list »

True North Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

True North Therapeutics Former Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
ATEL Capital Group Asset Manager Minority
Baxalta Corporation Minority
Baxter Ventures Corporate Venture Capital Minority
Biogen Corporation Minority
Cowen Healthcare Investments Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

True North Therapeutics FAQs

  • When was True North Therapeutics founded?

    True North Therapeutics was founded in 2013.

  • Where is True North Therapeutics headquartered?

    True North Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of True North Therapeutics?

    True North Therapeutics has 17 total employees.

  • What industry is True North Therapeutics in?

    True North Therapeutics’s primary industry is Drug Discovery.

  • Is True North Therapeutics a private or public company?

    True North Therapeutics is a Private company.

  • What is the current valuation of True North Therapeutics?

    The current valuation of True North Therapeutics is .

  • What is True North Therapeutics’s current revenue?

    The current revenue for True North Therapeutics is .

  • How much funding has True North Therapeutics raised over time?

    True North Therapeutics has raised $142M.

  • Who are True North Therapeutics’s investors?

    ATEL Capital Group, Baxalta, Baxter Ventures, Biogen, and Cowen Healthcare Investments are 5 of 18 investors who have invested in True North Therapeutics.

  • Who are True North Therapeutics’s competitors?

    BioMarin Pharmaceutical, Protalix Biotherapeutics, Dicerna Pharmaceuticals, Renova Therapeutics, and Cell Signaling Technology are some of the 63 competitors of True North Therapeutics.

  • When was True North Therapeutics acquired?

    True North Therapeutics was acquired on 28-Jun-2017.

  • Who acquired True North Therapeutics?

    True North Therapeutics was acquired by Bioverativ Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process